These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 34745006)

  • 41. Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats.
    Li L; Konishi Y; Morikawa T; Zhang Y; Kitabayashi C; Kobara H; Masaki T; Nakano D; Hitomi H; Kobori H; Nishiyama A
    J Pharmacol Sci; 2018 Jun; 137(2):220-223. PubMed ID: 29983235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological Management of Diabetic Nephropathy.
    Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
    Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
    Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
    Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
    BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The predictability of renin-angiotensin-aldosterone system factors for clinical outcome in patients with acute decompensated heart failure.
    Nakada Y; Takahama H; Kanzaki H; Sugano Y; Hasegawa T; Ohara T; Amaki M; Funada A; Yoshida A; Yasuda S; Ogawa H; Anzai T
    Heart Vessels; 2016 Jun; 31(6):925-31. PubMed ID: 25964073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contemporary utilization of GLP1 receptor agonists and SGLT2 inhibitors in patients with diagnosed type 2 diabetes and cardiovascular disease in the United States.
    Al-Kindi SG; Janus SE; Neeland IJ; Rajagopalan S
    J Diabetes Complications; 2022 Jul; 36(7):108224. PubMed ID: 35667964
    [No Abstract]   [Full Text] [Related]  

  • 49. Renin angiotensin aldosterone system and glycemia in pregnancy.
    Chen YP; Li J; Wang ZN; Reichetzeder C; Xu H; Gong J; Chen GJ; Pfab T; Xiao XM; Hocher B
    Clin Lab; 2012; 58(5-6):527-33. PubMed ID: 22783584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease.
    Ravindran S; Munusamy S
    J Cell Physiol; 2022 Feb; 237(2):1182-1205. PubMed ID: 34713897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.
    van den Heuvel M; Batenburg WW; Jainandunsing S; Garrelds IM; van Gool JM; Feelders RA; van den Meiracker AH; Danser AH
    J Hypertens; 2011 Nov; 29(11):2147-55. PubMed ID: 21941204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
    Lim S; Eckel RH; Koh KK
    Atherosclerosis; 2018 May; 272():33-40. PubMed ID: 29547706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
    Sinha B; Ghosal S
    Diabetes Res Clin Pract; 2019 Apr; 150():8-16. PubMed ID: 30794833
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease.
    Gay HC; Yu J; Persell SD; Linder JA; Srivastava A; Isakova T; Huffman MD; Khan SS; Mutharasan RK; Petito LC; Feinstein MJ; Shah SJ; Yancy CW; Kho AN; Ahmad FS
    Am J Cardiol; 2023 Feb; 189():121-130. PubMed ID: 36424193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel therapeutic agents for the treatment of diabetic kidney disease.
    Hartman RE; Rao PSS; Churchwell MD; Lewis SJ
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1277-1293. PubMed ID: 32799584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
    Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S
    Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GLP-1 Receptor Agonists and Kidney Protection.
    Greco EV; Russo G; Giandalia A; Viazzi F; Pontremoli R; De Cosmo S
    Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination therapy with SGLT2 inhibitors for diabetic kidney disease.
    Cai Y; Liu X; Xu G
    Biomed Pharmacother; 2020 Jul; 127():110192. PubMed ID: 32559844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.